Skip to Content
Merck
All Photos(1)

Documents

B1110000

Bifonazole

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-(p,α-Diphenylbenzyl)imidazole

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H18N2
CAS Number:
60628-96-8
Molecular Weight:
310.39
MDL number:
MFCD00865567
UNSPSC Code:
41116107
PubChem Substance ID:
329773163
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

bifonazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

c1ccc(cc1)C(c2ccc(cc2)-c3ccccc3)n4ccnc4

InChI

1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H

InChI key

OCAPBUJLXMYKEJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bifonazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Bifonazole is an imidazole-based anti-fungal agent with broad spectrum activity against many fungi, molds, yeast and some Gram-positive bacteria. Bifonazole inhibits ergosterol biosynthetic protein 28 and Cytochrome P450 2B4.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yonghong Zhao et al.
The Journal of biological chemistry, 281(9), 5973-5981 (2005-12-24)
To better understand ligand-induced structural transitions in cytochrome P450 2B4, protein-ligand interactions were investigated using a bulky inhibitor. Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and induces a type II binding spectrum in 2B4dH(H226Y), a modified enzyme previously
Salomé El Hage et al.
Archiv der Pharmazie, 344(6), 402-410 (2011-03-25)
Two series of chlorinated benzhydryl imidazole and triazole derivatives were synthesized and tested in vitro against representative strains of potent pathogenic bacteria (Staphylococcus aureus CIP 4.83, Escherichia hirae CIP 5855, Pseudomonas aeruginosa CIP 82118, Escherichia coli CIP 53126) and fungi
M Arabatzis
Clinical and experimental dermatology, 37(4), 370-373 (2012-03-24)
This is a report, the first to my knowledge, of secondary nail-apparatus involvement by Aureobasidium pullulans in a patient with onycholysis related to hypothyroidism. Complete cure of the lesions was seen after 2 weeks of itraconazole and 2 months of
Saban Gürcan et al.
Mikrobiyoloji bulteni, 43(1), 163-167 (2009-04-02)
Human infections caused by Alternaria alternata are more frequently reported in immunosupressive hosts. In this report, a rarely seen cutaneous infection, caused by A. alternata in an immunocompetent patient was presented. The patient (71-years-old, male) was admitted to the dermatology
Shinichi Watanabe et al.
Mycoses, 49(3), 236-241 (2006-05-10)
The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service